Znanstveni rad - Izvorni znanstveni rad
Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study
European Journal of Clinical Pharmacology, 79 (2023), 5; 643-655. https://doi.org/10.1007/s00228-023-03479-3

Trkulja, Vladimir; Kodvanj, Ivan

Citirajte ovaj rad

Trkulja, V. i Kodvanj, I. (2023). Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study. European Journal of Clinical Pharmacology, 79. (5), 643-655. doi: 10.1007/s00228-023-03479-3

Trkulja, Vladimir i Ivan Kodvanj. "Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study." European Journal of Clinical Pharmacology, vol. 79, br. 5, 2023, str. 643-655. https://doi.org/10.1007/s00228-023-03479-3

Trkulja, Vladimir i Ivan Kodvanj. "Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study." European Journal of Clinical Pharmacology 79, br. 5 (2023): 643-655. https://doi.org/10.1007/s00228-023-03479-3

Trkulja, V. i Kodvanj, I. (2023) 'Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study', European Journal of Clinical Pharmacology, 79(5), str. 643-655. doi: 10.1007/s00228-023-03479-3

Trkulja V, Kodvanj I. Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study. European Journal of Clinical Pharmacology [Internet]. 24.03.2023. [pristupljeno 15.06.2024.];79(5):643-655. doi: 10.1007/s00228-023-03479-3

V. Trkulja i I. Kodvanj, "Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study", European Journal of Clinical Pharmacology, vol. 79, br. 5, str. 643-655, Ožujak 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:402417. [Citirano: 15.06.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.